RightFit Trial Directory

Leukemia clinical trials in Philadelphia, PA

35 recruiting leukemia studies with a site in Philadelphia, PA.

All trials in Philadelphia, PA · All Leukemia trials

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Allentown, PA · Bethlehem, PA · East Stroudsburg, PA · +452 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Allentown, PA · Danville, PA · Hershey, PA · +112 more sites

RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.

Philadelphia, PA · +8 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Allentown, PA · Danville, PA · Hershey, PA · +222 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Danville, PA · Philadelphia, PA · Pittsburgh, PA · +132 more sites

RecruitingPhase 3NCT07007312

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Sponsor: Kura Oncology, Inc.

Philadelphia, PA · +43 more sites

RecruitingPhase 1 / Phase 2NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor: Syndax Pharmaceuticals

Philadelphia, PA · +21 more sites

RecruitingPhase not listedNCT05909501

Assessment of Geriatric Evaluations Impact on New AML Guidance

Sponsor: Abramson Cancer Center at Penn Medicine

Philadelphia, PA

RecruitingPhase 2NCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Sponsor: Allotera Therapeutics

Philadelphia, PA · +15 more sites

RecruitingPhase 1 / Phase 2NCT04925479

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Sponsor: Novartis Pharmaceuticals

Philadelphia, PA · +7 more sites

RecruitingPhase 3NCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Sponsor: Janssen Research & Development, LLC

Philadelphia, PA · Pittsburgh, PA · +56 more sites

RecruitingPhase 3NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor: Children's Oncology Group

Allentown, PA · Danville, PA · Hershey, PA · +183 more sites

RecruitingPhase 1NCT04972942

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Sponsor: New York Medical College

Philadelphia, PA · +15 more sites

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Allentown, PA · Danville, PA · Hershey, PA · +161 more sites

RecruitingPhase not listedNCT05702645

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Sponsor: Children's Oncology Group

Philadelphia, PA · Pittsburgh, PA · +70 more sites

RecruitingPhase 1NCT06247787

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Sponsor: Children's Oncology Group

Philadelphia, PA · Pittsburgh, PA · +17 more sites

RecruitingPhase not listedNCT03680677

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Sponsor: Abramson Cancer Center at Penn Medicine

Philadelphia, PA

RecruitingNot applicableNCT03810196

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Sponsor: Children's Hospital of Philadelphia

Philadelphia, PA

RecruitingPhase 1NCT07464951

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Stephan Grupp MD PhD

Philadelphia, PA

RecruitingPhase 1NCT05131022

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Sponsor: Nurix Therapeutics, Inc.

Philadelphia, PA · +17 more sites

RecruitingPhase 1 / Phase 2NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Sponsor: CellCentric Ltd.

Philadelphia, PA · +5 more sites

RecruitingPhase not listedNCT05978141

A Registry for People With T-cell Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

Philadelphia, PA · +24 more sites

RecruitingPhase not listedNCT01790152

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Sponsor: Children's Oncology Group

Philadelphia, PA · +68 more sites

RecruitingPhase 1 / Phase 2NCT06839456

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Sponsor: Children's Hospital of Philadelphia

Philadelphia, PA

RecruitingNot applicableNCT06892158

Massage Impact on Sleep in Pediatric Oncology

Sponsor: Children's Hospital of Philadelphia

Philadelphia, PA · +1 more sites

RecruitingPhase 1 / Phase 2NCT05674175

Co-administration of CART22-65s and huCART19 for B-ALL

Sponsor: Stephan Grupp MD PhD

Philadelphia, PA

RecruitingPhase 1 / Phase 2NCT04988555

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sponsor: Sumitomo Pharma America, Inc.

Philadelphia, PA · Pittsburgh, PA · +31 more sites

RecruitingPhase 1 / Phase 2NCT04990102

Phase IB/II of CPX-351 for Relapse Prevention in AML

Sponsor: Georgetown University

Philadelphia, PA · +2 more sites

RecruitingPhase 2NCT04276870

Orphan Indications for CD19 Redirected Autologous T Cells

Sponsor: Stephan Grupp MD PhD

Philadelphia, PA

RecruitingPhase 4NCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Sponsor: Eli Lilly and Company

Philadelphia, PA · +19 more sites

RecruitingEarly Phase 1NCT02356653

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Sponsor: Children's Hospital of Philadelphia

Philadelphia, PA

RecruitingPhase 2NCT05194397

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

Sponsor: Children's Hospital of Philadelphia

Philadelphia, PA · +2 more sites

RecruitingPhase 1 / Phase 2NCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Sponsor: Cellectis S.A.

Philadelphia, PA · +13 more sites

RecruitingPhase 1NCT06218628

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Sponsor: Fox Chase Cancer Center

Philadelphia, PA

Not yet recruitingNot applicableNCT07724652

The AYA Oncology Self-care Movement

Sponsor: Northwestern University

Philadelphia, PA · +3 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.